Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
₹92,433 Cr
32.22
5.91
34.92
0.19
14.61 %
16.24 %
0.4 %
342.66
62.9
₹19,084.84 Cr
₹28,152.91 Cr
₹9,759.88 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lupin
| -10.73 | -4.02 | 0.62 | 31.90 | 38.12 | 24.50 | 2.66 |
|
BSE Sensex
| -1.92 | -0.82 | -2.46 | 7.98 | 9.69 | 13.05 | 10.30 |
|
BSE Healthcare
| -8.57 | -5.54 | -4.42 | 17.84 | 19.23 | 23.63 | 10.21 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Lupin
| 79.43 | 80.31 | -22.83 | -5.01 | 26.67 | -9.27 | -4.41 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,488.00 | 1,17,087.88 | 23.47 | 18.12 | |
| 2,515.40 | 99,899.70 | 48.94 | 20.49 | |
| 1,725.90 | 4,06,363.37 | 35.54 | 17.76 | |
| 3,064.70 | 1,03,667.53 | 55.68 | 25.93 |
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars,... over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. Read more
1983
Manju D Gupta
Nilesh Gupta
Lupin
Mumbai, Maharashtra
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lupin Ltd stood at ₹ 25,482 Cr as on 31-Dec-24
The share price of Lupin Ltd is ₹2,103.00 (NSE) and ₹2,100.60 (BSE) as of 13-Feb-2025 11:44 IST. Lupin Ltd has given a return of 38.12% in the last 3 years.
Lupin Ltd has a market capitalisation of ₹ 92,433 Cr as on 12-Feb-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Lupin Ltd is 5.91 times as on 12-Feb-2025, a 7% premium to its peers’ median range of 5.51 times.
The P/E ratio of Lupin Ltd is 32.22 times as on 12-Feb-2025, a 8% discount to its peers’ median range of 34.92 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lupin Ltd and enter the required number of quantities and click on buy to purchase the shares of Lupin Ltd.
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
The promoter of Lupin Ltd is Lupin Investments Pvt Ltd. Lupin Investments Pvt Ltd owns 45.41 per cent of the total equity. The chairman of the company is Manju D Gupta , and the managing director is Nilesh Gupta..
There is no promoter pledging in Lupin Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,19,764
|
|
|
1,18,905
|
|
|
1,10,313
|
|
|
1,03,904
|
| Lupin Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
19.17
|
|
Operating margin(%)
|
16.82
|
|
Net Margin(%)
|
13.03
|
|
Dividend yield(%)
|
0.4
|
Yes, TTM profit after tax of Lupin Ltd was ₹2,869 Cr.
₹77.80
(
